Routine Cystoscopic Ureteral Stent Removal with or without Antibiotic Prophylaxis
International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)
DOI: 10.25258/ijcpr.18.7.192 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Dharmprakash N. K. und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Routine cystoscopic ureteral stent removal is commonly performed after uncomplicated urological procedures. However, the necessity of antibiotic prophylaxis during stent removal remains controversial, particularly in low-risk patients, because unnecessary antibiotic exposure may contribute to antimicrobial resistance and adverse effects.
Aim
To evaluate whether routine antibiotic prophylaxis was necessary for preventing post-procedural urinary tract infection (UTI) following uncomplicated cystoscopic ureteral stent removal. Materials and Methods: This prospective comparative clinical study included 100 adult patients undergoing routine outpatient cystoscopic ureteral stent removal following uncomplicated urological procedures, predominantly ureteroscopy and treatment of urinary calculi. Patients were divided into two equal groups: Group A (n=50) received antibiotic prophylaxis, while Group B (n=50) underwent stent removal without antibiotic prophylaxis. Patients with active UTI, significant immunosuppression, renal transplantation, urinary diversion, long-term stenting, or complex urological conditions were excluded. Baseline clinical characteristics, pre-procedural urine findings, post-procedural urinary symptoms, and infectious complications were assessed. Patients were followed for 30 days after stent removal.
Results
The mean age of the study population was 46.2 ± 13.0 years, and 62% were male. The two groups were comparable regarding demographic characteristics, diabetes mellitus, previous UTI, indication for stenting, preceding urological procedure, and duration of stent indwelling (P>0.05). Ureteric calculi were the most common indication for stent placement (69%), and ureteroscopy was the most frequent preceding procedure (73%). Post-procedural urinary symptoms were comparable between the groups. Symptomatic UTI occurred in 2 patients (4%) in the antibiotic group and 1 patient (2%) in the no-antibiotic group (P=0.56). Culture-confirmed UTI showed a similar distribution, with 2 cases (4%) in the antibiotic group and 1 case (2%) in the no-antibiotic group (P=0.56). No patient developed febrile UTI, pyelonephritis, urosepsis, or required hospital admission. Escherichia coli was the most frequently isolated organism (66.7%), followed by Klebsiella pneumoniae (33.3%).
Conclusion
Routine antibiotic prophylaxis did not significantly reduce the incidence of symptomatic or culture-confirmed UTI following uncomplicated cystoscopic ureteral stent removal in this low-risk study population. An antibiotic-sparing approach may therefore be appropriate for carefully selected patients without active urinary infection or major risk factors. However, larger multicentre prospective studies are required to establish definitive risk-based recommendations for antibiotic prophylaxis.
Zitieren
APA
K., D. N., Gupta, K. K., & N, S. B. (2026). Routine Cystoscopic Ureteral Stent Removal with or without Antibiotic Prophylaxis. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.192
Vancouver
K. DN, Gupta KK, N SB. Routine Cystoscopic Ureteral Stent Removal with or without Antibiotic Prophylaxis. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.192
BibTeX
@article{K2026,
author = {K., Dharmprakash N. and Gupta, Kaushal Kumar and N, Shivananda B.},
title = {Routine Cystoscopic Ureteral Stent Removal with or without Antibiotic Prophylaxis},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {07},
doi = {10.25258/ijcpr.18.7.192}
}
EUVIMED